CD44 and neoplasm: According to Nagaya et al. (2019), CD44-targeting PIT could synergize with PD-1 ICB therapy to completely reject both primary irradiated and non-irradiated distant CD44-positive MC38 tumor metastases in a systemic immune response known as the abscopal effect [255].